Novartis Stock Plummets After Three Trial Setbacks in a Week
Novartis shares plummeted nearly 9% on Tuesday, marking the Swiss pharmaceutical giant’s third major pipeline setback in a single week and threatening its long-term financial growth targets. According to CNBC, the sharp sell-off was triggered by a failed late-stage trial for the muscle-wasting disorder drug del-desiran, sending the stock toward its worst single-day performance since March 2020.
The compounding failures have severely shaken investor confidence just as the company faces impending patent cliffs for established blockbusters like Entresto.
The HARBOR Study Failure and the Avidity Acquisition Fallout
The core of Tuesday’s market reaction centers on the global Phase III HARBOR study evaluating del-desiran in patients with myotonic dystrophy type 1. According to CNBC and Invezz reporting, the trial failed to demonstrate a statistically significant improvement over placebo in video hand-opening time, a primary endpoint used to assess muscle stiffness.
Del-desiran was acquired as part of Novartis’s $12 billion purchase of Avidity Biosciences last year, designed to anchor the company’s neuromuscular pipeline. Barclays analysts noted that del-desiran and the cardiovascular drug pelacarsen represented roughly $5 billion in risk-adjusted peak sales opportunities. With del-desiran faltering, the financial viability of the Avidity acquisition faces renewed skepticism.
Shreeram Aradhye, President of Development and Chief Medical Officer at Novartis, addressed the scientific hurdles in a statement reported by CNBC and Invezz:
A Cascade of Pipeline Obstacles Threatens Long-Term Outlook
Tuesday’s announcement follows a brutal week for the pharmaceutical firm. On Monday, Novartis disclosed that its pelacarsen drug failed to reduce cardiovascular events in a late-stage trial. Just days prior, the company announced it had paused eight clinical trials for an experimental cell therapy, rap-cel, following the deaths of three patients.
Vontobel analysts previously estimated that del-desiran could generate peak annual sales of $3 billion, assigning the drug a 50% probability of success. The stock traded down at 112.56 Swiss francs on Tuesday following the broader market decline.
Despite the setbacks, Novartis maintains its official guidance for net sales to grow at a compound annual rate of 5% to 6% between 2025 and 2030. However, equity research teams at Jefferies expressed skepticism, noting in a Tuesday morning note covered by CNBC that the growth target will likely be perceived as unattainable without further mergers and acquisitions.
Valuation Pressures and the Path Forward
The string of clinical disappointments places intense pressure on management’s business development strategies. While a late-stage trial for the multiple sclerosis treatment remibrutinib recently delivered a clinically meaningful delay in disability progression, analysts emphasize that replacing the lost potential of del-desiran and pelacarsen remains an uphill battle.
Barclays and Jefferies analysts agree that future confidence relies heavily on pipeline readouts slated for 2028, such as data for del-brax, leaving the company vulnerable to activist investor pressure in the interim.
As Novartis evaluates the full HARBOR dataset and engages health authorities regarding the regulatory path for del-desiran, leadership must prove that its remaining pipeline can offset looming patent expiries.